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A B S T R A C T
Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still
not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver
disease. However, immediately after transplantation, the liver graft becomes infected by circulating virus, re-
sulting in accelerated progression of liver disease. Although the efficacy of HCV treatment using direct-acting
antivirals has improved significantly, immune compromised LT-patients and patients with advanced liver disease
remain difficult to treat. As an alternative approach, interfering with viral entry could prevent infection of the
donor liver. We generated a human monoclonal antibody (mAb), designated 2A5, which targets the HCV en-
velope. The neutralizing activity of mAb 2A5 was assessed using multiple prototype and patient-derived HCV
pseudoparticles (HCVpp), cell culture produced HCV (HCVcc), and a human-liver chimeric mouse model.
Neutralization levels observed for mAb 2A5 were generally high and mostly superior to those obtained with
AP33, a well-characterized HCV-neutralizing monoclonal antibody. Using humanized mice, complete protection
was observed after genotype 1a and 4a HCV challenge, while only partial protection was achieved using gt1b
and 6a isolates. Epitope mapping revealed that mAb 2A5 binding is conformation-dependent and identified the
E2-region spanning amino acids 434 to 446 (epitope II) as the predominant contact domain. Conclusion: mAb
2A5 shows potent anti-HCV neutralizing activity both in vitro and in vivo and could hence represent a valuable
candidate to prevent HCV recurrence in LT-patients. In addition, the detailed identification of the neutralizing
epitope can be applied for the design of prophylactic HCV vaccines.
1. Introduction
Approximately 130–170 million people are chronically infected
with hepatitis C virus (HCV) worldwide. HCV infection represents a
major health problem since more than 70% of infected individuals
develop chronic viral hepatitis that can ultimately progresses to liver
cirrhosis and hepatocellular carcinoma (HCC). While a prophylactic
vaccine is still lacking, the landscape of HCV treatment has been
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revolutionized by the approval of multiple new generation protease,
NS5A and polymerase inhibitors. Nevertheless, certain patient popula-
tions, such as liver transplant recipients, patients with advanced liver
disease and genotype (gt) 3 infected individuals remain difficult to treat
(Zeuzem et al., 2014). Moreover, recent evidence suggests that direct-
acting antivirals (DAA)-induced cure does not eliminate the risk of
hepatocellular carcinoma, in particular in patients with fibrosis, and
even may be associated with HCC recurrence early after HCV clearance
(Baumert et al., 2017; Conti et al., 2016; Llovet and Villanueva, 2016;
Reig et al., 2016). Upon liver transplantation (LT), re-infection of the
liver graft by circulating virus is unavoidable and viral variants with
resistance-associated substitutions have been identified in patients that
failed DAA-based therapy. Furthermore, DAA treatment in solid organ
transplantation can result in severe adverse effects (Hogan et al., 2017).
Besides its pivotal role in viral entry, the E2 envelope protein re-
presents the main target for the host's adaptive immune system and the
induction of neutralizing antibodies (nAbs). The study of HCV has long
been hampered by the lack of robust in vitro and in vivo models.
Retroviral particles pseudotyped with HCV envelope glycoproteins
(HCVpp) and the HCV cell culture system (HCVcc) have proven very
valuable to study virus binding and entry (Catanese and Dorner, 2015).
On the other hand, mice with chimeric humanized liver currently re-
present the most reliable in vivo animal model alternative to the
chimpanzee for the study of HCV (Mercer et al., 2001; Meuleman et al.,
2005). We and others have used this model extensively to study HCV
biology, to determine the neutralizing capacity of monoclonal and
polyclonal antibodies that target the virus or one of its receptors, and
for the evaluation of novel therapeutic approaches (Mesalam et al.,
2016).
The impact of cell-mediated immunity on HCV clearance has been
shown in multiple studies (Heim and Thimme, 2014; Park and
Rehermann, 2014), whereas it remains less clear to what extent the
humoral immune response plays a role. Nevertheless, spontaneous re-
covery from HCV infection seems to be associated with the early de-
velopment of broadly neutralizing antibodies (Ndongo et al., 2010;
Osburn et al., 2014) and highly neutralizing antibodies have been de-
tected in injection drug users that tested HCV RNA negative (Swann
et al., 2016b). In addition, high levels of broad neutralizing antibodies
have been associated with reduced disease severity, lower viral loads
and higher SVR rates after pegylated-interferon/ribavirin therapy
(Hamed et al., 2008; Ndongo et al., 2010; Swann et al., 2016a). Fur-
thermore, weak or absent antibody neutralization in HCV/HIV co-in-
fected and agammaglobulinemia patients respectively, correlate with
the severity of liver disease and lower diversity within the HCV qua-
sispecies pool (Booth et al., 1998; Maurin et al., 2015). Altogether,
these findings reflect the importance of the humoral immune response
during HCV infection.
Interference with HCV entry by passive immunization or by vaccine-
induced nAbs represents an attractive approach for the prevention of
HCV infection, especially in chronically infected patients undergoing
liver transplantation (Felmlee et al., 2016). Polyclonal antibodies from
HCV infected patients as well as monoclonal antibodies (mAbs) were
able to protect chimpanzees and humanized mice from experimental
HCV infection (Bukh et al., 2015; Desombere et al., 2016; Eren et al.,
2006; Law et al., 2008; Meuleman et al., 2011; Morin et al., 2012;
O'Shea et al., 2016; Vanwolleghem et al., 2008). In addition, mAb MBL-
HCV1 significantly delayed viral rebound following liver transplanta-
tion, while complete protection was reported when combined with
DAAs (Chung et al., 2013; Smith et al., 2017). The limitation of this
antibody is however that it is associated with rapid viral escape without
compromising viral fitness. In the present study, we describe the de-
velopment and in vitro and in vivo characterization of a novel human
monoclonal antibody (2A5) targeting the HCV envelope.
2. Materials and methods
(A more detailed description of all material and methods can be
found in an online supplement).
2.1. Generation of mAb 2A5
Hybridomas producing mAb 2A5 directed to the envelope of HCV
were generated as described before (Depraetere et al., 2001). In brief,
human peripheral blood mononuclear cells (PBMC) collected from an
individual chronically infected with HCV of gt1b were injected in the
spleen of two optimally conditioned NOD-SCID mice (originally pur-
chased from Charles River) (1 × 107 cells per animal). Six days later
the mice were bled and their plasma anti-E1E2 antibody titer was
measured using an in-house immunoassay (EIA). On day 7, the mouse
displaying the highest anti-E1E2 titer was sacrificed and a cell sus-
pension of the spleen was prepared that was then mixed with K6H5/B5
heteromyeloma cells (kindly provided by Dr. Kris Thielemans, Free
University of Brussels (VUB), Brussels, Belgium) at a 4:1 ratio. Poly-
ethylene glycol 1500 (50% v/v; Boehringer Mannheim, Mannheim,
Germany) was added for 2 min and then washed away. Fused cells
(5 × 104) were cultured in microtiter plates in 200 μL of medium
supplemented with human recombinant insulin (10 μg/mL, Boehringer
Mannheim), ouabain (1 μM, Sigma, St. Louis, MO), hypoxanthine-
aminopterin-thymidine (Life Technologies, Belgium) and 10% v/v BM
Condimed HI (Boehringer Mannheim). Cultures were replenished with
fresh medium every other day and individual wells were checked for
cell growth first and anti-E1E2 IgG production subsequently. Eight anti-
E1E2 IgG-producing cultures were selected, subcloned several times
and further expanded. After initial screening for reactivity against the
HCV E1E2 protein (EIA), the neutralizing potential of the supernatant
of all growing cultures was tested with neutralization assays using HCV
pseudoparticles (HCVpp) of gt1a (isolate H77c). The human mAb with
the strongest neutralizing capacity was selected and designated 2A5.
Hybridoma cells producing mAb were propagated in a two-compart-
ment bioreactor (Integra) and the antibody-containing culture super-
natant was changed weekly. mAb 2A5 was purified using a protein G
column (GE Healthcare Life Sciences) and concentrated using Amicon
Centrifugal filters (Merck Millipore). The mAb 2A5 content of this
preparation was determined using a human IgG ELISA Quantitation Set
(Bethyl Laboratories).
2.2. In vitro experiments
The binding affinity of mAb 2A5 was tested using an enzyme im-
munoassay (EIA) with cell lysates containing recombinant HCV E1E2
glycoproteins as previously described (Owsianka et al., 2005). The
neutralization potential of this mAb was also tested using HCVpp and
HCVcc systems. A detailed description of cells, antibodies and methods
used in all in vitro experiments can be found in the online supplement.
2.3. In vivo HCV challenge
Human liver chimeric mice were produced as previously described
(Mercer et al., 2001; Meuleman et al., 2005). Briefly, two weeks after
birth, homozygous uPA+/+-SCID mice were transplanted by intra-
splenic injection with 106 cryopreserved primary human hepatocytes
(donor HH223; BD Biosciences, Belgium). In passive immunization
studies, mice were intraperitoneally injected with 1 mg of mAb 2A5
three days before challenge with a 100% infectious dose of gt1a (mH77;
104 IU), gt1b (mP05; 104 IU), gt4a (mED43; 104 IU) or gt6a (mHK6a;
105 IU) (Desombere et al., 2016; Meuleman et al., 2011). Viremia was
quantified using the COBAS Ampliprep/COBAS TaqMan HCV test
(Roche Diagnostics). The limit of quantification (LOQ) in diluted
plasma was 750 IU/mL. The study protocol was approved by the local
animal ethics committee.
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2.4. Statistical analysis
Statistical significance was calculated by Wilcoxon's matched-pairs
signed-ranks test using GraphPad Prism software version 6. P-values
below 0.05 were considered statistically significant.
Fig. 1. Binding characteristics of mAbs 2A5 and AP33. (A)mAbs 2A5 and AP33 were serially diluted and incubated on plates pre-coated with cell lysates containing HCV E1E2 derived
from prototype isolates (H77c, JFH1, S52) and gt1b patient-derived viral isolates (P09_VA, P12_VA, P12_1091). Dose-dependent binding is expressed as percentage of maximal binding
(mean ± standard deviation (error bars)). (B) EC50 values were calculated from dose-response curves shown in (A). All conditions were performed in duplicate.
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3. Results
3.1. mAb 2A5 efficiently binds and neutralizes most prototype and patient-
derived HCV strains
We compared the binding and neutralizing activity of mAb 2A5
with the broadly neutralizing anti-E2 mAb AP33, using the envelopes of
infectious HCV variants isolated from: (i) prototype HCV-strains and (ii)
gt1b patient-derived strains which were selected during transmission to
humanized mice. The relative affinity of mAbs 2A5 and AP33 for E1E2
derived from prototype HCV gt1a (H77c), 2a (JFH1) and 3a (S52) and
for chronic patient isolates P09_VA, P12_VA and P12_1091 was de-
termined using GNA-capture ELISA (Fig. 1a). Dose-response experi-
ments demonstrate that mAb 2A5 usually performs better than mAb
AP33 (P = 0.031). The apparent affinity depends on the isolate with
half maximal effective concentration (EC50) values ranging between
0.109 and 1.215 μg/mL (Fig. 1b).
The neutralization potential of mAb 2A5 was first investigated using
HCVpp expressing envelope glycoproteins from 3 prototype viruses
(H77c, JFH1 and S52) and 5 patient-derived gt1b viral variants
(P09_VA, P09_VB, P09_779, P12_VA and P12_1091). Viral entry was
inhibited in a dose-dependent manner and for most viral strains the
neutralizing potential of mAb 2A5 was superior to that of AP33
(P = 0.25) (Fig. 2a). Similar to the E1E2-binding data, viral strain S52
(gt3a) was difficult to neutralize and viral strain P12_1091 (gt1b) was
very efficiently neutralized (Fig. 2b). To extend these observations and
to elaborate on the cross-neutralizing potential of mAb 2A5, HCVpp
neutralization experiments were performed using HCV envelope gly-
coproteins derived from clinical samples covering additional geno-
types/strains (gt1b (UKN1B5.23), gt2a (UKN2A1.2 and J6), gt2b
(UKN2B2.8), gt3a (UKN3A13.6), gt4 (UKN4.11.1), gt5 (UKN5.15.7)
and gt6 (UKN6.5.8)). The obtained results demonstrate that neu-
tralization by mAb 2A5 is mainly strain dependent and that strains J6
and UKN4.11.1 can hardly be neutralized (Table S1).
To further corroborate the neutralizing potency of mAb 2A5 we
utilized the HCVcc system covering multiple HCV strains: gt1a (H77c/
JFH1 and full length TNcc), gt1b (J4/JFH1), gt2a (JC1), gt3a (S52/
JFH1; UKN3A1.28c; and UKN3A13.15), gt4a (ED43/JFH1), gt5a
(SA13/JFH1), gt6a (HK6a/JFH1) and gt7a (QC69/JFH1) (Fig. 3a and
Fig. S1). Overall, results demonstrate that mAb 2A5 efficiently neu-
tralizes most HCV strains, with half maximal inhibitory concentration
(IC50) values comparable or superior to the neutralization observed
with AP33 (P = 0.0078). The gt6a strain HK6a/JFH1, which could not
be neutralized by AP33, was very efficiently neutralized by 2A5
(IC50 = 0.007 μg/mL). Strain S52/JFH1 was barely neutralized, in line
with the E1E2 binding and HCVpp neutralization results (Fig. 3b).
3.2. Protection by mAb 2A5 from HCV challenge in vivo
The neutralizing potency of mAb 2A5 was also tested in vivo. Human
liver chimeric uPA-SCID mice were passively immunized with mAb 2A5
or left untreated (control) and challenged three days later with HCV of
gt1a (mH77c), gt1b (mP05), gt4a (mED43) and gt6a (mHK6a) (Fig. 4).
After challenge with mH77c, all four 2A5-treated mice remained HCV
RNA negative throughout the 8-week observation period, whereas the 3
control mice became viremic within the first week after virus injection.
Similarly, challenge with mED43 resulted in complete protection of all
2A5-treated mice. After challenge with mHK6a, all 2A5-treated mice
remained HCV RNA negative until the second week after challenge. At
week 3, HCV RNA became detectable in one 2A5-treated mouse
(6.35 × 103 IU/mL), while the others remained undetectable until
week 8. Again, HCV RNA was readily detected in the control mice from
week 1 onwards. Challenge with the difficult-to-neutralize mP05 isolate
(Fafi-Kremer et al., 2010; Fofana et al., 2012) ultimately resulted in
protection in 2 out of 6 treated mice.
Although the human IgG plasma levels in 2A5-treated mice were
very variable (measured at week 1, ranging from 23 to 202 μg/mL), no
correlation could be found between the circulating mAb levels and the
viral kinetics (Table S2). To test the presence of resistant variants in
non-protected mice (gt1b and gt6a), we amplified the E1E2 region of
the virus present in the plasma from treated and control mice. Sequence
analysis showed comparable viral quasispecies variability in the E2
region between treated and control groups, and no resistant mutants
could be identified (results not shown).
3.3. mAb 2A5 mainly recognizes the E2-region spanning amino acids 434 to
446
In order to delineate the epitope that is targeted by mAb 2A5 we
initially scanned the complete E1E2 sequence using a custom-made
peptide microarray (PEPperCHIP®, PEPperPRINT GmbH, Germany)
wherein the complete E1E2-sequence, originating from a dominant
sequence within the quasispecies of the patient from whom mAb 2A5
was generated, is displayed as 15-mer peptides with an overlap of 14
AA. The peptide sequences and complete chip layout are detailed in
supplementary File S1. Using this microarray platform, the E2-region
AA434-443 was identified as a major binding region for mAb 2A5 (Fig.
S2).
The involvement of this region in 2A5-binding was confirmed and
further scrutinized using an in-house enzyme EIA with peptides span-
ning AA433-443 derived from different gt1a and gt1b natural viral
isolates (AA sequence see Fig. 5a). From these binding experiments we
could conclude that 2A5-binding is unchanged when (i) position AA440
is occupied by amino acid G or A, or (ii) position AA437 is occupied by
amino acid W or F. At position AA434, N confers better binding than Q
and at position AA438, L is much more favorable for binding than F
(Fig. 5b). To elaborate on the anchor residues, mutant peptides were
generated wherein residues at position AA433 and AA443 were re-
placed by alanine (L433A and Y443A) (Fig. 5c). Results demonstrate
that position 443 plays a critical role in optimal binding. In addition,
comparison of 2A5-binding to the peptide AA433-443 with that to a
peptide covering the region AA433-452, showed enhanced affinity to-
wards the longer peptide indicating additional contact residues within
the region adjacent and downstream from AA443 (Fig. 5d). To further
elaborate on 2A5-anchor residues within region AA433-452, the
binding efficiency was compared between the peptide representing the
prototype isolate H77c and its alanine-substituted counterparts (Fig. 5e
and f). Our data indicate that AA434, AA438, AA441, AA442, AA443
and AA446 are important for 2A5 binding, with AA442 and AA443
being major anchor residues.
To confirm these results, our peptide binding assays were repeated
in the context of full-length E1E2 protein. 2A5-binding was tested for
binding to wild-type H77c E1E2 protein and its mutants in which the
AA spanning regions 419–447, 522–536 and 612–617 were alanine-
substituted (Fig. 5g). Based on the reduction in mAb binding, our
analyses revealed several regions within E2 that are critical for 2A5-
binding: AA424-428, AA437-443, AA446, AA530 and AA612-617. Re-
sults obtained for AA437-446 are largely comparable with EIA-peptide
data and are shown in Fig. 5f. The finding that several non-adjacent
regions within E2 are involved in binding and that mutation at position
C429 (forming a disulfide bond) completely abrogates binding, suggests
that mAb 2A5 recognizes a conformational epitope.
Alignment of the E2-region spanning AA420-452 of the different
HCV strains used in the binding and neutralization studies is shown in
Fig. 6a. Residues found critical for 2A5-binding in that region are
highlighted and, for each strain, the simplified AA-motif is shown on
the right. Based on aforementioned experiments, a neutralization-
hierarchy is deduced for the different motifs that, for most motifs, can
largely predict the neutralization outcome (Fig. 6b). However, two
motifs are linked to opposing neutralization data: (i) motif N-I-LFY-K is
present in strains TNcc (IC50: 1.49 μg/mL) and S52 (IC50:> 90 μg/mL),
and (ii) motif N-L-LFY-R is present in strains JFH1 (IC50: 0.02 μg/mL),
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UKN1B5.23 (IC50: 0.57 μg/mL) and UKN4.11.1 (IC50: 38 μg/mL). Fur-
thermore, the motif Q-L-LFY-K, which was very efficiently neutralized
in vitro, could barely be neutralized in vivo (mP05).
3.4. The epitope recognized by mAb 2A5 is conformational
To investigate whether the epitope recognized by mAb 2A5 is linear
or conformational, binding to native and denatured H77c E1E2 protein
was compared. mAbs recognizing conformational (mAb HC84.26) or
linear (HC33.1 and AP33) epitopes were included for comparison
(Fig. 7a). The EIA-results showed complete loss of 2A5-binding to de-
natured E1E2 proteins while mAbs HC33.1 and AP33 retained more
than 50% of their binding activity. As expected mAb HC84.26 did not
recognize denatured HCV E1E2 proteins. These results clearly demon-
strate the conformation-dependency of 2A5 binding.
To analyze whether competition occurs between mAb 2A5 and
other known mAbs for binding to the HCV envelope, a competition EIA
was set-up wherein anti-E2 (AP33, HC33.1, HC84.26, HC-1AM, CBH-7,
1:7 and 3/11) and anti-E1 (A4) mAbs were used as competing anti-
bodies for 2A5-binding to E1E2 of isolate H77c (Fig. 7b). Our results
demonstrate that, apart from the anti-E1 mAb, all mAbs compete for
2A5-binding. As expected, only mAb 3/11 and HC33.1 compete for
AP33-binding. These mAbs were previously shown to recognize similar
epitopes.
4. Discussion
The HCV envelope proteins contain different immunogenic regions,
but not all of these are suitable for vaccine design. The HVR1 region is
highly immunogenic, but is known for its high mutation rate that en-
ables viral escape; and antibodies directed to this region may interfere
with broad-neutralizing ones (Keck et al., 2016a; Prentoe et al., 2016).
Likewise, the immunogenic E2-epitope domain A induces antibodies
with non-neutralizing activity (Keck et al., 2007). Recently it was
shown that E2 protein lacking the three variable regions (HVR1, HVR2
and igVR; Δ123) induced antibodies that cross-neutralized HCV in vitro
Fig. 2. Neutralization of HCVpp by mAbs 2A5 and AP33. (A) HCVpp expressing E1E2 derived from prototype isolates (H77c, JFH1, S52) and gt1b patient-derived viral isolates
(P09_VA, P09_VB, P09_779, P12_VA and P12_1091) were incubated for 1 h at 37 °C with serial dilutions of mAbs 2A5 or AP33 and added to Hep3B cells. HCVpp entry was analyzed by
luciferase reporter gene expression and normalized to isotype controls. Neutralization is expressed as % neutralization (mean ± standard deviation (error bars)). (B) IC50 values were
calculated from dose-response curves shown in (A). All conditions were performed in quadruplicate.
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Fig. 3. Neutralization of HCVcc by mAbs 2A5 and AP33. (A) HCVcc expressing the structural proteins of genotype 1a, 1b, 2a, 3a, 4a, 5a, 6a and 7a isolates were pre-incubated with
three-fold serial dilutions of mAbs 2A5, AP33 or a control Ab. The mixture was transferred to Huh7.5.RFP cells and incubated for 4 h before washing. Two days later, HCV-infected foci
were visualized using an NS5A-specific antibody and counted. Results are expressed as percentage of infectivity (mean ± standard deviation (error bars)). (B) IC50 values were
calculated from dose-response curves shown in (A). All conditions were performed in triplicate.
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(Vietheer et al., 2017). During the last decade, several mAbs that target
different E2-epitopes have been developed and the concept of passive
immunization for protection from HCV challenge has been investigated
in different studies. Treatment of chimpanzees with human mAb MBL-
HCV1 protected from challenge with gt1a HCV (Morin et al., 2012). In
another study, the same mAb showed a delay of HCV recurrence in
patients after liver transplantation (Chung et al., 2013). In a most re-
cent proof-of-concept study involving liver transplantation patients,
combination therapy of sofosbuvir and mAb MBL-HCV1 completely
protected from HCV re-infection (Smith et al., 2017). The murine mAb
AP33, targeting a conserved region within E2, has been extensively
studied and shows broad cross-neutralizing activity to most HCV gen-
otypes (Desombere et al., 2016; Owsianka et al., 2005; Tarr et al., 2006;
Urbanowicz et al., 2015).
In the present study, we generated a human mAb, designated 2A5,
from a gt1b chronic HCV patient. We demonstrate that mAb 2A5 effi-
ciently binds and neutralizes most HCV strains, with EC50 and IC50
values comparable or lower than those of AP33. However, the gt6a
strain HK6a/JFH1, which was insensitive to AP33, was very efficiently
neutralized by 2A5. This chimeric HK6a/JFH1 virus contains cell
culture adaptive mutations at multiple sites including the region en-
compassing the epitope critical for AP33 binding, which might explain
its resistance to AP33 neutralization (Gottwein et al., 2009). The gt3a
chimeric HCVcc S52/JFH1 was barely neutralized, confirming the re-
sults obtained with the HCVpp system. Remarkably, mAb 2A5 was able
to neutralize two other gt3a chimeric viruses (UKN3A1.28c/JFH1 and
UKN3A13.15/JFH1), supporting the concept that neutralization sensi-
tivity is determined at strain rather than genotype level (Tarr et al.,
2011; Urbanowicz et al., 2015). Despite the sometimes relatively high
coefficient of variation, which is inherent to the neutralization assays
used, our data indicates that mAb 2A5 seems to be the most broadly
neutralizing antibody identified so far. In contrast to most recently
published studies that use ‘prototype’ strains for neutralization assays
and animal challenge (Akazawa et al., 2013; Bukh et al., 2015; Xiao
et al., 2015), we also included patient-derived viral variants. These
variants probably better reflect the diversity of natural HCV infection
and are therefore an important tool for the evaluation of HCV-specific
mAbs.
During the last decade, the human liver chimeric mouse model has
proven to be very valuable as an alternative to the chimpanzee for the
Fig. 4. mAb 2A5 protects human liver chimeric mice from HCV challenge. Three days before viral infection, humanized mice were passively immunized with 1 mg of mAb 2A5. Mice
were challenged with mH77 (gt1a, 104 IU HCV RNA), mP05 (gt1b, 104 IU), mED43 (gt4a, 104 IU) or mHK6a (gt6a, 105 IU). Viremia was quantified until week 8 post infection. 2A5-
treated and control mice are represented by closed and open circles, respectively. Mice that scored HCV RNA negative are displayed below the dashed line representing the limit of
quantification (LOQ; HCV RNA<750 IU/mL).
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in vivo study of HCV (Mesalam et al., 2016). Using this small animal
model, we previously reported that passive immunization with poly-
clonal antibodies targeting the HCV envelope could protect from HCV
infection (Meuleman et al., 2011; Vanwolleghem et al., 2008). We now
utilized this model to evaluate whether mAb 2A5 can confer protection
from viral challenge with different HCV isolates. A single dose of 1 mg
of mAb 2A5 was able to confer protection against mH77c (gt1a),
mED43 (gt4a) and HK6a (gt6a) challenge. Since control mice became
HCV RNA positive early after infection, the protection can clearly be
attributed to the presence of mAb 2A5 in circulation. This in vivo result
correlates with the observed in vitro neutralization data. The efficacy of
mAb 2A5 was also tested against ‘difficult-to-neutralize’ strains. For
this, we used a gt1b viral escape isolate, obtained from a liver-trans-
planted patient (mP05) (Fafi-Kremer et al., 2010). After mP05 chal-
lenge, only partial protection was found, but breakthrough mice
showed delayed viral kinetics during the first week(s) post inoculation.
Previously, it was demonstrated that this isolate was highly resistant to
antibody neutralization and can very efficiently enter cells by optimal
receptor usage (Fafi-Kremer et al., 2010; Fofana et al., 2012). The single
mAb dose used in our current study corresponds to 100 mg/kg, which is
lower compared to other studies using either higher and/or multiple
doses (Keck et al., 2016b; Law et al., 2008; O'Shea et al., 2016).
To delineate the epitope targeted by mAb 2A5 we initially scanned
the complete E1E2 sequence. Using a peptide microarray in combina-
tion with traditional peptide-EIA, we could localize the main epitope to
the E2-region spanning AA434-446, also known as ‘epitope II’ (Zhang
et al., 2007). This region has also been shown to be recognized by nAbs
(Keck et al., 2012), as well as peptide-affinity-enriched neutralizing
polyclonal sera (Tarr et al., 2012). Surprisingly and somewhat con-
troversially, this region is also thought to be recognized by antibodies
that may interfere with the neutralization mediated by antibodies re-
cognizing the AP33-eptitope (epitope I; AA412-423) (Zhang et al.,
2007). Using alanine mutants the main 2A5-anchor residues within
AA433-446 were identified as AA434, AA438, AA441, AA442, AA443
and AA446; with AA442F/L and AA443Y being critical for binding.
However, this does not exclude that other aromatic amino acids might
be tolerated at the latter positions. We scanned this binding motif for all
strains used in the study and correlated the motif with the observed
neutralization. Importantly, we found identical motifs that induce op-
posite neutralization depending on the strain (motif N-I-LFY-K and
motif N-L-LFY-R). Furthermore, the motif Q-L-LFY-K, which was very
efficiently neutralized in vitro, could barely be neutralized in vivo
(mP05). These data reveal the importance of additional contact residues
outside region AA420-452. Full-length E1E2 protein alanine scanning
identified the regions AA424-428, AA530 and AA612-617 as critical for
mAb 2A5 binding.
Finally, we could demonstrate that mAb 2A5 recognizes a con-
formational epitope, which is in line with the several non-adjacent
binding regions within E2 and the abrogation of binding in the C429A
protein mutant. Interestingly, 4 out of 5 E2-regions recognized by mAb
Fig. 5. Epitope mapping of mAb 2A5. The binding pattern of mAb 2A5 was analyzed using gt1a- and gt1b-derived sequences, of which the E2 region spanning amino acids (AA)433–443
of the different clones (cl) is shown (A). After incubation with surface-attached peptides, bound antibodies were detected with an HRP-conjugated anti-human secondary antibody. The
2A5-binding pattern was analyzed using mAb (50 μg/mL) and peptides spanning AA-region 433–443, derived from naturally occurring gt1a (clone a-b) and gt1b (clone c-d) isolates (B),
and A-substituted peptides (L433A, Y443A) from gt1a_clone a and gt1b_clone d (C). Binding was normalized to the best binding peptide (100% binding). (D) To elaborate on the length of
the epitope, the efficiency of 2A5-binding was compared between peptides covering region AA433-443 and peptides including an additional upstream sequence (AA433-452), all derived
from gt1a_clone a. (E) To further elaborate on 2A5-anchor residues within the region of interest (AA433-452), the binding efficiency was compared between peptides derived from the
prototype isolate H77c and their A-substituted counterparts. The corresponding color-codes, representing the different A-substituted sequences, and the % binding relative to native H77c
at 10 μg mAb/mL are shown in (F). (G) To confirm these results and to reveal additional contact residues for mAb binding, epitope mapping was done using E1E2 proteins of the H77c
isolate with A-substitutions in 3 regions (AA419-447, AA522-536 and AA612-617). 2A5-binding to full-length native and mutated E1E2 cell lysates was analyzed. Results represent the %
binding relative to E1E2_H77c at 10 μg mAb/mL (F, G).
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Fig. 6. Main binding motif recognized by mAb 2A5. (A) Alignment of the E2-region spanning AA420-452 of the different HCV strains used in the binding and neutralization studies.
Residues found critical for mAb 2A5-binding (AA433, AA438, AA441, AA442, AA443 and AA446) are highlighted and, for each strain, the simplified AA-motif is shown on the right. (B) A
hierarchy in neutralization potential was deduced for the binding motifs. The AA-motif corresponding to the H77c strain is marked with a black box. AA-motifs shown on the left-side of
‘> ’ have better neutralization properties compared to AA-motifs shown on the right-side. Motifs from ‘difficult to neutralize’ strains HCV-S52, JC1 and J6 are highlighted in red boxes.
Motifs from HCV-strains that can be efficiently neutralized by 2A5 (P12_1091, HK6a and UKN5.15.7) are indicated in green boxes. (*) represents identical motifs with different
neutralization efficiencies.
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2A5, overlap with regions previously described to be important for
neutralization (reviewed in (Sautto et al., 2013)): epitope II (AA434-
446), domain B (AA523-540), W (AA616) and (AA698). Furthermore,
the recognition of epitope II and domain B overlaps with the recogni-
tion by the mAbs AR3 (Law et al., 2008).
The strong and cross-neutralizing activity of 2A5, shown by HCVpp
and HCVcc assays and confirmed in vivo, makes this human monoclonal
antibody a valuable candidate for passive immunization, either alone or
in combination with other antiviral agents, especially in patients un-
dergoing liver transplantation. Immunoprevention of HCV infection
using a broadly neutralizing antibody may be superior to post-trans-
plant DAA treatment, especially to prevent damage to the liver graft as
well as to minimize the risk of HCC and treatment-induced adverse
effects. Furthermore, the identification of highly conserved residues
within the E2 provides valuable information for the development of a
highly efficacious, broad-spectrum prophylactic HCV vaccine.
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